Business Wire

NY-CPV

2.4.2024 15:01:33 CEST | Business Wire | Press release

Share
Introducing New York Golf Club and Player Roster

Cohen Private Ventures (CPV), the family office of Steven A. Cohen, is proud to officially unveil New York Golf Club (NYGC) and its four-player roster of PGA TOUR stars featuring Rickie Fowler, Xander Schauffele, Matt Fitzpatrick and New York-native Cameron Young ahead of the inaugural 2025 TGL presented by SoFi season.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240402326760/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New York Golf Club team roster: Cameron Young, Matt Fitzpatrick, Xander Schauffele, Rickie Fowler (Photo: Business Wire)

New York is synonymous with world class, and its golf scene is no exception. Steeped in the history of the sport, with some of the greatest and most iconic courses in the world, NYGC is ready to build upon its rich legacy of golf and redefine what it means to be a golf club representing a city known for its constant reinvention. NYGC is excited to represent the tri-state area in this innovative and accessible version of the sport.

“New Yorkers expect and deserve the best, and we couldn’t be more excited to have four of the best players in the world serve as an extension of the thriving golf and sporting culture of our city and region,” said Steve Cohen, owner of the NYGC and the New York Mets. “Rickie, Xander, Matt, and Cameron’s unwavering dedication to the sport, successful track records, and passion for winning is undisputable, and we look forward to watching them compete on golf’s newest stage.”

TEAM NAME & LOGO

New York City is the greatest city in the world, and NYGC embraces the privilege and responsibility that comes with representing the five boroughs and surrounding communities. NYGC will build upon our world-class golfing and sports heritage to deliver a team New York fans can be proud of.

NYGC’s logo is inspired by New York’s state bird, the Eastern Bluebird. These birds are commonly found where forests meet fields, and particularly on golf courses. Our design features a dynamic swinging club crafted into the form of a wing with four grooves, one for each of our players. The circle pays homage to the circles on our scorecards and the iconic NYC Subway circle.

MEET THE PLAYERS

Fowler is one of the most popular players on the PGA TOUR. Since turning professional in 2009, he has recorded 10 professional wins, including the 2015 PLAYERS Championship. His most recent title came at the 2023 Rocket Mortgage Classic in July. Fowler brings a wealth of team golf experience as a veteran of five U.S. Ryder Cup teams, three U.S. Presidents Cup teams, one World Cup, Walker Cup and Palmer Cup teams from his time as an amateur player. He also represented the U.S. in the 2016 Olympic Games.

“I am thrilled to be joining New York Golf Club for the inaugural TGL season,” said Fowler. “It is an incredible opportunity to represent one of the greatest cities in the world, and I look forward to competing in 2025.”

Schauffele, currently No. 5 in the Official World Golf Ranking, has been a top-10 player in the world for the better part of the last five years and regularly placing in the Top 10 of major championships. Since turning professional in 2015, he has recorded seven PGA TOUR titles, two DP World Tour wins and an Olympic Gold Medal in Tokyo. He was named the PGA TOUR Rookie of the Year in 2016-2017 and represented the U.S. in two Presidents Cup teams and two Ryder Cup teams.

“I’ve built my career on a foundation of hard work, grit, and determination, which couldn’t better reflect the people of New York City,” said Schauffele. “It’s a true honor to both grow the game and represent this incredible city.”

Fitzpatrick became England’s first major champion since 2016 when he won the 2022 U.S. Open at The Country Club in Brookline, Massachusetts, joining Jack Nicklaus as the only players to have won a U.S. Open and U.S. Amateur at the same venue. Since turning professional in 2014, Fitzpatrick has recorded two PGA TOUR titles and eight international victories, and represented England on three European Ryder Cup teams. His most recent PGA TOUR victory came at the RBC Heritage in April 2023.

“Working with the team at Cohen Private Ventures on the launch of New York Golf Club has been an incredible experience,” said Fitzpatrick. “New York is one of the greatest cities in the world, and I could not be more excited to continue to deepen my connections there.”

The New York-native Young is quickly becoming a fan favorite on the PGA TOUR. In 2022, Young earned Rookie of the Year honors when he became the seventh player since 1980 to collect five runner-up finishes in a season, including a second-place finish at The Open Championship and tying for third at the PGA Championship. He made his debut on the Presidents Cup team in 2022. Cameron’s father David Young, recently retired after over 20 years as Sleepy Hollow Country Club’s Head Golf Professional.

“Having grown up a New Yorker, first learning to play at Sleepy Hollow, the opportunity to represent New York Golf Club feels surreal,” said Young. “Alongside Rickie, Xander, and Matt, I am confident we are going to be a highly competitive team in the upcoming TGL season.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240402326760/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye